Alpha Tau Expands Pancreatic Cancer Trial with First Italian Patient Treated via Alpha DaRT
Event summary
- Alpha Tau Medical treated the first pancreatic cancer patient in Italy using Alpha DaRT, marking the first global protocol to permit both endoscopic ultrasound (EUS) and percutaneous delivery methods.
- The study, conducted at the University of Verona’s Pancreas Institute, aims to enroll up to 15 patients with locally advanced pancreatic cancer.
- Pancreatic cancer has a high mortality rate in Italy, with 14,903 deaths annually and a five-year survival rate of just 11-12%.
- This trial follows the first European patient treated in France’s ACAPELLA trial in April 2026 and complements the ongoing IMPACT trial in the U.S.
The big picture
Alpha Tau’s expansion into Italy with its Alpha DaRT treatment reflects a strategic push to diversify its clinical trial footprint and validate its technology across different healthcare systems. The inclusion of percutaneous delivery broadens the potential patient population, addressing a critical gap in treatment options for those with locally advanced pancreatic cancer. This move aligns with the company’s global strategy to position Alpha DaRT as a versatile and accessible therapy in the oncology space.
What we're watching
- Clinical Efficacy
- Whether Alpha DaRT’s dual delivery approach will demonstrate superior feasibility and safety in treating locally advanced pancreatic cancer.
- Regulatory Pathway
- The pace at which Alpha Tau can secure regulatory approvals for Alpha DaRT in multiple regions, given the ongoing global trials.
- Market Adoption
- How the inclusion of interventional radiologists and oncologists will expand the reach of Alpha DaRT beyond traditional surgical and endoscopic teams.
Related topics